Company
Company Mission and Values
- MINVASYS created in May 2003 is an international privately held company based in the Paris area, France.
- MINVASYS focuses on bifurcation treatment with dedicated devices. Nile Croco® for coronary bifurcations and Twin-One® for carotid bifurcations.
- MINVASYS will concentrate its future activities within the next years in the interventional cardiology and neuroradiology fields and respond to the needs of the medical community and patients.
- MINVASYS will capitalize on the strong experience of its collaborators and medical advisors to develop and market innovative, efficient, safe and cost effective devices.
- MINVASYS intends to pursue its growth strategy based upon the market dynamics and the economical factors driving the health communities all around the world.
- MINVASYS is the constructive partner in innovative development and marketing of MINimally INVasive VAScular SYStems.
Company profile
- MINVASYS is a fully operative structure comprising Research & Development, Manufacturing, Quality Assurance / Regulatory Affairs and Sales & Marketing functions.
- Based on a 20 year experience within the interventional cardiology field, MINVASYS benefits of an expertise which enables it to offer a wide range of extremely performing medical devices.
- MINVASYS, designer and manufacturer of medical devices for interventional procedures complies with the 93/42/CEE directive. The company is ISO 9001(2008) - ISO 13485(2003) certified. Hence giving full support to its international partners for local market authorizations.
- MINVASYS is actively supported by its current business partners throughout the world.
For more information on our local distribution network, please contact us.
Our mission
Based on its strong experience, MINVASYS objective is to become the reference from technological, medical and market point of view for bifurcation treatment. MINVASYS is currently focusing on coronary and carotid bifurcations, bringing to the market two very innovative systems :
- Nile Pax®, dedicated stent and delivery device for coronary bifurcation.
- Twin-One®, efficient temporary occlusion balloon for carotid treatment.
The next generations are in progress with the Pax program (Polymer Free Paclitaxel Abluminal Coating) and an integrated embolic protection system while stent for carotid applications.
Animal trial on Drug Eluting Balloon Danubio®, is completed and FIM is planned to be initiated in the fall 2010. Drug Eluting Balloon has the potential to be an effective additional device which can be combined with Nile Pax® bifurcated stent.
Investors
History
- MINVASYS created in May 2003 is an international privately held company based in the Paris area, France.
- MINVASYS focuses on bifurcation treatment with dedicated devices. Nile Croco® for coronary bifurcations and Twin-One® for carotid bifurcations.
- MINVASYS will concentrate its future activities within the next years in the interventional cardiology and neuroradiology fields and respond to the needs of the medical community and patients.
- MINVASYS will capitalize on the strong experience of its collaborators and medical advisors to develop and market innovative, efficient, safe and cost effective devices.
- MINVASYS intends to pursue its growth strategy based upon the market dynamics and the economical factors driving the health communities all around the world.
- MINVASYS is the constructive partner in innovative development and marketing of MINimally INVasive VAScular SYStems.